Why is Artemis Medicare falling/rising?

Recent Price Movement and Market Context

On 16 December, Artemis Medicare’s stock closed at ₹282.90, marking a gain of ₹1.45 or 0.52% for the day. This rise is part of a broader upward trend, with the stock having gained 4.56% over the past week and 5.09% in the last month, significantly outperforming the Sensex benchmark, which recorded marginal gains of 0.02% and 0.14% respectively over the same periods. Notably, the stock has been on a consecutive eight-day winning streak, delivering a cumulative return of 5.82% during this span.

Despite this recent strength, Artemis Medicare’s year-to-date performance remains negative at -9.88%, and it has underperformed the broader market over the last year with a decline of 14.75%, compared to the Sensex’s 3.59% gain. However, the company’s longer-term track record is impressive, with a three-year return of 264.56% and a remarkable five-year return exceeding 1,186%, far outpacing the Sensex’s respective 38.05% and 81.46% gains.

Technical Strength Supports Price Appreciation

The stock’s technical indicators provide further support for the recent price rise. Artemis Medicare is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bullish momentum. This technical positioning often attracts investor interest, contributing to the stock’s outperformance relative to its sector by 0.61% on the day. However, it is worth noting that investor participation has declined somewhat, with delivery volumes on 15 December falling by 37.62% compared to the five-day average, suggesting some caution among traders despite the upward trend.

Fundamental Strength Underpinning the Rally

Artemis Medicare’s recent price appreciation is underpinned by strong fundamental performance. The company has demonstrated a healthy ability to service its debt, with a low Debt to EBITDA ratio of 1.34 times, indicating manageable leverage and financial stability. Operating profit has grown at an impressive annual rate of 82.15%, reflecting robust business expansion and operational efficiency.

In its latest financial results declared in September 2025, Artemis Medicare reported a net profit growth of 41.51%, marking the seventh consecutive quarter of positive earnings. The company’s operating cash flow for the year reached a high of ₹139.08 crores, while its return on capital employed (ROCE) stood at a strong 13.34% for the half-year period. Additionally, the debt-equity ratio remains low at 0.32 times, further highlighting the company’s prudent capital structure.

Valuation metrics also favour the stock. With a return on equity (ROE) of 10.8% and a price-to-book value of 5.1, Artemis Medicare trades at a discount relative to its peers’ historical valuations. Despite the stock’s negative one-year return of -14.75%, the company’s profits have risen by 46.9% over the same period, resulting in a PEG ratio of 1.7, which suggests that the stock’s price may not fully reflect its earnings growth potential.

Risks and Market Challenges

Despite the positive momentum, investors should be mindful of certain risks. The company’s management efficiency is a concern, with an average ROE of 9.51%, indicating relatively low profitability per unit of shareholders’ funds. This metric suggests that while the company is growing, it may not be optimising returns for equity holders as effectively as some competitors.

Moreover, Artemis Medicare has underperformed the broader market over the past year, with a negative return of 14.75% compared to the BSE500’s modest gain of 0.72%. This underperformance may reflect market scepticism or sector-specific challenges that could temper investor enthusiasm in the near term.

Nevertheless, the stock’s recent gains and strong operational results indicate that investors are increasingly recognising its growth potential and improving fundamentals, which have contributed to the current upward price trajectory.

Conclusion

In summary, Artemis Medicare’s share price rise on 16 December is supported by a combination of strong fundamental performance, positive earnings momentum, and favourable technical indicators. While the stock has faced challenges over the past year, its robust operating profit growth, consistent positive quarterly results, and attractive valuation metrics have helped it outperform its sector and sustain an upward trend in recent trading sessions. Investors should weigh these strengths against ongoing risks related to management efficiency and market underperformance when considering the stock’s outlook.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →